The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy.

Autor: Perrin A; Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Electronic address: andry.perrin@gmail.com., Venderink W; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Patak MA; Department of Radiology, Klinik Hirslanden, Zürich, Switzerland., Möckel C; Department of Urology, Klinik Hirslanden, Zürich, Switzerland., Fehr JL; Department of Urology, Klinik Hirslanden, Zürich, Switzerland., Jichlinski P; Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Porcellini B; Department of Radiology, Klinik Hirslanden, Zürich, Switzerland., Lucca I; Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Futterer J; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Valerio M; Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Jazyk: angličtina
Zdroj: Urologic oncology [Urol Oncol] 2021 May; Vol. 39 (5), pp. 297.e9-297.e16. Date of Electronic Publication: 2020 Dec 17.
DOI: 10.1016/j.urolonc.2020.11.041
Abstrakt: Objectives: To evaluate the utility of in-bore multiparametric magnetic resonance-guided biopsy of the prostate (IB) in patients with visible lesion/s and previous negative software-based multiparametric magnetic resonance imaging/ultrasonography fusion-targeted biopsy of the prostate (FTB).
Patients and Methods: We retrospectively analysed prospectively maintained database including consecutive men undergoing IB from March 2013 to October 2017 in 2 European centres expert in this procedure. We selected men with the following criteria: No previous treatment for prostate cancer (CaP), multiparametric magnetic resonance imaging (mpMRI) lesion(s) PIRADS score ≥ 3, FTB showing no clinically significant cancer (csCaP), and subsequent IB. Patient's characteristics, mpMRI findings, biopsy technique, and histopathological results were extracted. The primary outcome was to determine the detection rate of csCaP, defined as any Gleason pattern ≥ 4. A multivariable analysis was performed to identify predictors of positive findings at IB.
Results: Fifty-three men were included. Median age was 68 years (interquartile range [IQR] 64-68), median Prostate-Specific Antigen (PSA) was 7.6 ng/ml (IQR 5.2-10.9), and median prostate volume was 59 ml (IQR 44-84). Fifty-six lesions with PIRADS score 3 in 9 cases (16%), 4 in 30 cases (54%), and 5 in 17 cases (30%) were detected. FTB was performed in all cases using a transrectal approach with 3 different platforms (Toshiba, Koelis, and Artemis). Median time between FTB and IB was 3 months (IQR 1-7). A median of 2 cores per lesion were collected with IB (IQR 2-3). No cancer, clinically insignificant and clinically significant cancer were found in 33 (59%), 9 (16%), and 14 (25%) targeted lesions, respectively. Median maximum cancer core length and maximum positive percentage were 9 mm (3-13) and 55% (21%-80%). The only predictor of csCaP on IB was prostate volume (P = 0.026) with an ideal cut-off at 70 ml.
Conclusion: One in 4 patients with previous negative FTB, IB was able to detect csCaP. According to this study, IB would be of particularly useful in patients with large glands.
Competing Interests: Declaration of competing interest No conflict of interest was declared by the authors.
(Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: